Skip to content

Acufex Suretac PAC

by Acufex Microsurgical, Inc.

510(k) K930538

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK930538 Date13 Sep 1993ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Acufex Suretac(R) Pac
510(k) Number
FDA Product Code
JDR
Device Class
Class II
Regulation
21 CFR Part 888.3030
Advisory Committee
Orthopedic
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Acufex Suretac PAC is a catheter-based device classified as an embolization catheter (product code JDR). It is designed for use in interventional radiology procedures to deliver embolic agents to vascular targets, such as uterine fibroids, to occlude blood flow and reduce lesion size.

This device is supplied sterile and intended for single-use in controlled clinical settings. It is regulated under FDA 510(k) clearance (K930538) as a Class II Orthopedic device, adhering to traditional premarket notification requirements. No additional sterility, MRI safety, or reusable specifications are noted in the regulatory data.

Other devices from Acufex Microsurgical, Inc.

See all devices from Acufex Microsurgical, Inc. →

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What types of vascular procedures is the Acufex Suretac PAC catheter specifically designed for, and how does it work in those settings?

    The Acufex Suretac PAC is designed for interventional radiology procedures where embolic agents need to be delivered to specific vascular targets. Its primary use is to occlude blood flow to lesions like uterine fibroids, helping to reduce their size by cutting off their blood supply. The catheter is inserted into the vascular system and guides embolic materials directly to the target area, ensuring precise delivery for effective treatment.

  • Is the Acufex Suretac PAC catheter reusable, or is it intended for single-use only? How does this affect its clinical use?

    The Acufex Suretac PAC is explicitly intended for single-use only in controlled clinical settings. This design choice ensures sterility and safety, as reuse could compromise integrity and introduce infection risks. Clinicians must adhere to single-use protocols to maintain compliance with regulatory standards and patient safety.

  • How is the Acufex Suretac PAC catheter supplied, and what should clinicians consider when handling or storing it?

    The device is supplied sterile by the manufacturer, which means it is pre-packaged and ready for immediate clinical use without additional sterilization. Clinicians should store it in a clean, dry environment, protected from extreme temperatures or physical damage, to preserve sterility and functionality until use. Always follow manufacturer guidelines for unpacking and handling to avoid contamination.

  • What regulatory pathway does the Acufex Suretac PAC follow, and what does this mean for its use in clinical practice?

    The Acufex Suretac PAC was cleared through the FDA 510(k) process (K930538) under the Orthopedic advisory committee (OR) and classified as a Class II device with a product code of JDR (Embolization Catheter). This means it is considered substantially equivalent to a predicate device and adheres to traditional premarket notification requirements. Clinicians can rely on this clearance for its intended use in embolization procedures, though they should always verify current regulatory status before use.